Fibrotech launches diabetic nephropathy study, partnering talks
By Nuala Moran
Friday, March 21, 2014
LONDON – Fibrotech Therapeutics Pty has begun dosing in the phase Ib trial of its lead molecule FT011 in treating diabetic nephropathy and is now involved in “intensive discussions” to partner the small-molecule antifibrotic.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.